Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Camellino, D; Dejaco, C; Martini, F; Cosso, R; Bianchi, G.
Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases
REUMATISMO. 2025; 77(1): 1796
Web of Science

Co-authors Med Uni Graz: Dejaco Christian
Altmetrics:
Abstract:: The objective of this case series is to describe the efficacy and safety of baricitinib (BARI) in a group of patients with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA). These patients were treated with BARI due to either a refractory disease course or the unavailability of tocilizumab because of the pandemic. A total of six patients (five females and one male, median age 64 years, range 50-83) were treated with BARI. Two of them had isolated PMR, two had PMR with associated large vessel (LV)GCA, one had LV-GCA presenting as fever of unknown origin, and one had cranial-GCA. All patients reported improvement with BARI. At the time of starting BARI, patients were taking a median prednisone dose of 8.75 mg/day (range 0-25), and the four patients with PMR had a median PMR-activity score of 23.3 (indicating high disease activity), which decreased to 1.58 after 6 months of treatment with BARI. Two of them could stop glucocorticoids (GC) and continue BARI monotherapy. One patient suffered from pneumonia, and BARI was therefore stopped. No other adverse events attributable to BARI were detected. Our case series supports previous reports suggesting the efficacy of Janus kinase inhibitors as a GC-sparing strategy in PMR and GCA. due to AE (4). Janus kinase inhibitors (JAK-i) are a class of immunomodulators that act on the intracellular transduction pathways and are currently used to treat several immune-mediated diseases, including, but not limited to, rheumatoid arthritis, spondyloarthropathies, and inflammatory bowel diseases (5). Compelling pre-clinical and clinical evidence suggests the efficacy of JAK-i in treating large vessel vasculitis (LVV) (6, 7). Herein, we report six patients with PMR and/or GCA successfully treated with baricitinib (BARI).
Find related publications in this database (Keywords): polymyalgia rheumatica; giant cell arteritis; large vessel vasculitis; JAK-inhibitors; positron emission tomography.